<DOC>
	<DOCNO>NCT02363751</DOCNO>
	<brief_summary>Open-label , non-randomized , multicenter , phase II , single arm non comparative trial evaluate toxicity efficacy gemcitabine plus platinium salt combination bevacizumab first-line set metastatic collect duct carcinoma .</brief_summary>
	<brief_title>Study Gemcitabine+Platinium Salt+Bevacizumab Combination Metastatic Collecting Duct Carcinoma ( BEVABEL )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Ductal</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>1 . Patients age ≥ 18years inclusion , 2 . Patients histologically confirm metastatic collecting duct carcinoma , 3 . Available tumor sample centralize read anatomopathologist , 4 . Patients without nephrectomy , 5 . At least one measurable lesion per RECIST criterion ( RECIST v1.1 ) , 6 . No prior chemotherapy antiangiogenic drug ( naive patient ) , 7 . No irradiation within 4 week inclusion , 8 . Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L , 9 . Platelets ≥ 100 x 109/L , 10 . Hemoglobin ≥ 9 g/dL , 11 . Hepatic function : AST ALT ≤ 1.5 x ULN ( ≤ 4 x ULN case liver metastasis ) ; total bilirubin ≤ 1.5 x ULN ; alkaline phosphatase &lt; 2 x ULN ( ≤ 4 x ULN case bone metastasis ) , 12 . Renal function : creatinine clearance ≥ 60 mL/min ( MDRD calculation method ) , 13 . Absence proteinuria baseline define &lt; 0.3 g protein urine sample &lt; 0.5 g/24h00 urine collection , 14 . Prothrombin time ( TP ) partial thromboplastin time ( PTT ) strictly less 50 % deviation normal limit , international normalize ratio ( INR ) strictly 2 , Note : The use fulldose oral parenteral anticoagulant well aspirin clopidogrel permit long INR PTT within therapeutic limit ( accord medical standard institution ) patient stable dose anticoagulant least two week time study enrolment . Prophylactic use anticoagulant allow . 15 . ECG normal sinus rhythm , 16 . ECOG Performance Status : 0 2 , 17 . Estimated life expectancy ≥ 12 week , 18 . Patients received information sheet , date sign informed consent form , 19 . Patient childbearing potential ( female patient : study entry menstrual period negative pregnancy test ) must agree use two medically acceptable method contraception ( one patient one partner ) study 6 month last study treatment intake . 20 . Patients must willing able comply schedule visit , treatment plan , laboratory test study procedure , 21 . Patients affiliate Social Security System , 1 . Treatment investigational agent , participation another clinical trial within 28 day prior enrolment , 2 . Prior systemic treatment chemotherapy antiangiogenic tyrosine kinase inhibitor axitinib , sunitinib , sorafenib , pazopanib , tivozanib , mTOR inhibitor ( Temsirolimus everolimus ) target VEGF drug bevacizumab VEGF trap , 3 . Evidence current central nervous system ( CNS ) metastases spinal cord compression . If CNS metastasis suspect , patient undergo MRI CTScan brain ( contrast , possible ) within 28 day prior inclusion , 4 . Another histological type renal cancer 5 . Other malignancy within 3 year prior inclusion ( except basal cell carcinoma skin and/or situ carcinoma cervix , and/or pT1/a bladder cancer ) , 6 . Uncontrolled hypertension ( ≥ 160 mm Hg systolic and/or ≥ 90 mm Hg diastolic ) receive medication , 7 . Cardiovascular disorder : congestive heart failure ≥ NYHA II , myocardial infarction coronary artery bypass graft previous six month , ongoing severe unstable angina , 8 . LVEF value strictly less 50 % , 9 . Current recent ( within 2 week study enrolment ) initiation aspirin , clopidogrel ) , oral parenteral anticoagulant thrombolytic agent therapeutic purpose . 10 . History clinically significant hemorrhagic thromboembolic event past six month , know inherited predisposition bleed thrombosis History abdominal fistula , GI perforation , intraabdominal abscess active GI bleeding within 6 month prior first study treatment ; History haemoptysis ≥ grade 2 ( define ≥ 2.5 mL bright red blood per episode ) within 1 month study enrolment , 11 . Patients underwent , accord investigator , significant surgery limit , abdominal , thoracic neurologic surgery within 28 day first treatment administration patient wind already heal first treatment administration patient underwent minor surgical procedure include placement vascular access device , within 2 day first study treatment , 12 . Patients active ulcer , 13 . Patients untreated bone fracture , 14 . Peripheral neuropathy grade ≥ 2 ( Toxicity Criteria ( CTCAE ) v4.0 ) , 15 . Patients active infection require intravenous antibiotic time first study treatment , 16 . In opinion investigator , evidence severe uncontrolled systemic disease ( e.g . unstable uncompensated respiratory , cardiac , hepatic renal disease ) , acute chronic medical condition would make patient inappropriate study , 17 . Immunocompromised patient , include know seropositivity human immunodeficiency virus ( HIV ) , 18 . Known hypersensitivity component investigational drug excipients , 19 . Pregnant lactate woman , 20 . Person deprive liberty judicial protection ( include guardianship ) , 21 . Patients significantly alter mental status prohibit understand study psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule condition , opinion investigator , would preclude participation trial . Those condition discuss patient registration trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Bellini</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>